Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Finland has been experiencing steady growth in recent years, driven by various underlying macroeconomic factors.
Customer preferences: Patients in Finland have been increasingly seeking personalized and targeted treatments for cancer, leading to a rise in demand for oncology drugs. Additionally, the aging population in Finland has contributed to the growth of the market, as cancer is more prevalent among elderly individuals.
Trends in the market: One major trend in the Finnish Oncology Drugs market is the shift towards immunotherapies and other innovative treatments. Pharmaceutical companies are investing heavily in research and development of these new treatments, which are expected to have better efficacy and fewer side effects compared to traditional chemotherapy drugs. Another trend is the growing importance of biosimilars, which are cheaper versions of biologic drugs that have lost patent protection. Biosimilars are becoming increasingly popular in Finland due to their lower cost and similar efficacy to the original drugs.
Local special circumstances: Finland has a well-established healthcare system that provides universal access to healthcare for all citizens. This has led to a high level of demand for oncology drugs, as patients have access to the latest treatments and therapies. Additionally, Finland has a strong pharmaceutical industry, with several local companies competing with multinational corporations in the market.
Underlying macroeconomic factors: The Finnish economy has been growing steadily in recent years, with a strong focus on innovation and technology. This has led to increased investment in the healthcare sector, including oncology drugs. Additionally, the Finnish government has implemented several policies to support the development of the pharmaceutical industry, such as tax incentives and funding for research and development. The country's membership in the European Union has also facilitated trade and investment in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
